Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.

J Immunother Cancer · 2019 · PMC6458744 · PMID 30975225

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

showed a trendp = 0.07so close (0.05 < p ≤ 0.1)

Patients who had received BRAF and MEK inhibitors treatment prior to the study showed a trend toward worse survival ( p = 0.07): for this group, 12-month and 24-month OS rates were 46% and 16%, respectively.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.